SUBSCRIBE

Breaking News on Supplements, Health & Nutrition - Europe US edition | APAC edition

Trends > Financial plays

Danone and Mead Johnson to make united Pfizer nutrition bid?

By Shane Starling , 27-Jan-2012
Last updated on 30-Jan-2012 at 13:11 GMT2012-01-30T13:11:10Z

Danone and Mead Johnson to make united Pfizer nutrition bid?

Danone and Mead Johnson may make a joint bid for the €8bn infant nutrition-dominated Pfizer nutrition business that is up for sale, according to press reports.

The Financial Times quoted “a lending source and a person with knowledge of the situation” commenting that a joint bid could avert any anti-trust issues derived from a single bid, a problem that is very real to the other main interested party, Nestlé.

The Danone-Mead Johnson idea may be submitted to Pfizer which has demanded all interested parties explain resolutions to any potential competition issues.

The UK, Ireland, New Zealand, Australia and Turkey are seen as anti-trust hotspots for Danone; China for Mead Johnson where it dominates the infant formula market.

Nestlé would have likely issues in Australia and Mexico.

“While we continue to evaluate a variety of options for our nutrition business including a sale, spin off or other transaction, our preference remains to favour one overall option rather than dividing assets and business operations,” a Pfizer spokesperson told the paper.

Commitment to drugs

Pfizer has said it wants to commit to evolving its pharma businesses as the principle reason for the sale of the division that turned over about €1.5bn in 2010.

The move has puzzled some analysts given Pfizer only took possession of the division in 2009, as part of the $68bn (€51.8bn) buy-out of Wyeth, and it has acquired a danish supplements business called Ferrosan in that time and establaished infant formula R&D partnerships.

Products in the division include the SMA Gold line of products for infants and children and Enercal supplements for adults. These products sell in more than 60 countries.

While there are those that are promoting a diversification strategy for pharma players faced with generic competition to something like €100bn+ in blockbuster drug sales as patents expire, Pfizer CEO Ian Read has made it clear his company is diving headlong into developing the next generation of blockbuster drugs.

It has indicated its animal nutrition business – which with human nutrition generated 8% of the giant’s income – may also go up for sale.

Related products

Live Supplier Webinars

Polyphenols tipped to become the way to innovate in Sports Nutrition
Fytexia
Alpha & Omega in Sports Nutrition – Using Omega 3’s and A-GPC to improve performance and recovery.
KD Pharma
Orally bioavailable standardized botanical derivatives in sport nutrition: special focus on recovery in post-intense physical activities
Indena
Collagen in motion: move freely and keep your injuries in check
Leading manufacturer of gelatine and collagen peptides
Life’s too short for slow proteins. Whey proteins hydrolysates: Fast delivery for enhanced performance
Arla Foods Ingredients
What it Takes to Compete and Win in Today’s Sports Nutrition Market
Capsugel
Sports Nutrition Snapshot: Key regional drivers and delivery format innovations
William Reed Business Media
Gutsy performance: How can microbiome modulation help athletes and weekend warriors
William Reed Business Media
Pushing the boundaries: Where’s the line between ‘cutting edge nutrition’ and doping
William Reed Business Media

On demand Supplier Webinars

High-amylose maize starch may reduce the risk of type 2 diabetes: what does this qualified health claim mean?
Ingredion
Balancing Innovation and Risk in Sports Nutrition Ingredients
NSF-International
Explaining bio-hacking: is there a marketing opportunity for food companies?
William Reed Business Media
Personalized Nutrition – how an industry can take part in shaping the future of Nutrition
BASF Nutrition & Health
Find out Nutritional and ingredient lifecycle solutions and strategies!
Roquette
Is the time rIpe for I-nutrition?
William Reed Business Media
The Advantage of Outsourcing Fermentation-based Manufacturing Processes
Evonik Health Care
All supplier webinars

Promotional Features